Hear how hepatitis B may be a curable disease in the next decade during Sunday’s AASLD State-of-the-Art Lecture “On the Horizon for Hepatitis B.” Robert G. Gish, MD, FAASLD, will moderate the session.
Thanks to a new commitee structure, the AGA International Committee has been able to expand its global educational efforts at #DDW19. Read about the additional offerings at this year’s meeting from Gilaad Kaplan, MD, MPH, AGAF, and Linda Rabeneck, MD, MPH.
Avinash G. Ketwaroo, MD, walks through sessions designed to meet the unique needs of DDW® attendees in the early stages of their careers in gastrointestinal medicine.
AASLD’s educational programming at DDW® is designed to provide a broad education on hot liver disease topics for general gastroenterologists and deeper learning for hepatologists seeking information on the latest research and treatment advances. Meena B. Bansal, MD, FAASLD, shares the sessions you won’t want to miss.
Will you be pinched for time at #DDW19? AGA’s Postgraduate Course course provides a concise and comprehensive update on the latest medical, scientific and technological advances in gastroenterology from the previous 12 months, designed for attendees who have limited time. Joseph Ahn, MD, MS, MBA, AGAF, and course co-directors explain more.
Join the editors of AASLD’s flagships journals for a comprehensive update, Hepatology Update: The Year in Review, on Saturday afternoon, May 18.
The management of cirrhosis has evolved at a rapid pace in recent years. During a case-based AASLD symposium on the final day of DDW® 2018, three experts reviewed the most recent developments in diuretic resistant/refractory ascites, recurrent/refractory hepatic encephalopathy and recurrent/refractory variceal bleeding. The panel was co-moderated by Catherine Frenette, MD, FAST, AGAF.
Alcoholic liver disease is getting a new name, alcohol-associated liver disease, or AALD. The disease is also getting new treatment approaches and new attention from researchers, clinicians and industry, according to Gyongyi Szabo, MD, PhD, FAASLD.
Nonalcoholic fatty liver disease (NAFLD), which is strongly linked to diabetes, high cholesterol and heart disease, has become increasingly common around the world, especially in
The addictive nature of opioids and the increasing number of overdoses and fatalities in America has been intensively researched and publicized, but there has been
